Effectiveness of Pharmaceutical Interventions in Hospitalized Patients
INFAR
1 other identifier
interventional
332
1 country
1
Brief Summary
The presence of multimorbidities is very common among the elderly, which become major consumers of medicines. The process of prescribing medicines for the elderly should be done with caution, as the use of some medications may present more risks than benefits in this range age. Potentially inappropriate prescribing for the elderly has become a global concern for the promotion of an adequate pharmacotherapy, it becomes essential to be aware of the effectiveness and safety of medicines and the knowledge of which drugs whose risks of serious adverse reactions outweigh the benefit of your referral. In this sense, the present study has aim to evaluate the effectiveness of pharmaceutical interventions in frequency of omission of drugs with proven efficacy for cardiovascular diseases and promotion of treatment prescription inappropriate and polypharmacy. A prospective quasi experimental before and after study will be carried out in elderly patients diagnosed with cardiovascular disease admitted to the Ana Nery hospital, Salvador, Bahia, Brazil. A convenience sample will be collected, the data will be released and revised in a database built in the SPSS software and analyzed in the program statistic R and SPSS. At the end of the study, it is expected a decrease in the frequency of omission of medications and promotion of prescription drugs inappropriate.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 2, 2021
CompletedStudy Start
First participant enrolled
February 4, 2021
CompletedFirst Posted
Study publicly available on registry
March 16, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 30, 2022
CompletedApril 12, 2022
April 1, 2022
12 months
February 2, 2021
April 10, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Effectiveness of pharmaceutical interventions measured by proportion of accepted interventions and all interventions
The acceptance of all pharmaceutical interventions related to inappropriate prescribed drugs and omission of prescription during the hospitalization of the patient will be evaluated, through study completion, an average of 1 year
Secondary Outcomes (3)
Incidence of polypharmacy in elderly people with cardiovascular diseases measured by prescription containing five or more drugs
First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year
Incidence of omission of prescription drugs with proven efficacy for cardiovascular diseases measured by the START criteria
First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year
Incidence of potentially inappropriate drug prescription in elderly people with cardiovascular diseases measured by the Beers criteria
First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year
Study Arms (1)
Pharmaceutical intervention
EXPERIMENTALA pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors
Interventions
A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs
Eligibility Criteria
You may qualify if:
- Clinical diagnosis of cardiovascular disease
- Discharge after 24 hours
You may not qualify if:
- \* Death
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Hospital Ana Nery
Salvador, Estado de Bahia, 40301-155, Brazil
Related Publications (2)
Gama RS, Passos LC, Amorim WW, Souza RM, Oliveira MG. Reducing Anticholinergic Burden in Hospitalised Older Adults: Analysis From the INFAR Study. Basic Clin Pharmacol Toxicol. 2026 Jan;138(1):e70160. doi: 10.1111/bcpt.70160.
PMID: 41345711DERIVEDGama RS, Passos LC, Amorim WW, Souza RM, Oliveira MG. Effectiveness of Pharmacist Interventions in Improving Medication Use in Hospitalised Older Patients Diagnosed With Cardiovascular Diseases: INFAR Before-and-After Study. J Eval Clin Pract. 2025 Jun;31(4):e70190. doi: 10.1111/jep.70190.
PMID: 40581959DERIVED
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Clinical Professor of Pharmacy and Evidence-based Health Care
Study Record Dates
First Submitted
February 2, 2021
First Posted
March 16, 2021
Study Start
February 4, 2021
Primary Completion
January 30, 2022
Study Completion
January 30, 2022
Last Updated
April 12, 2022
Record last verified: 2022-04